{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-033055","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.298102+00:00","generated_at":"2026-05-30T05:45:17.353854+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TG Therapeutics Q3 BRIUMVI revenue $83.3M, raises FY2024 guidance to $300-$305M","bullets":["BRIUMVI Q3 U.S. net sales $83.3M, up 15% QoQ and 230% YoY; full-year target raised to $300-$305M.","Net income $3.9M in Q3 vs $113.9M a year ago (prior period included $140M upfront payment); cash $341M.","Phase 1 trial of subcutaneous ublituximab initiated; FDA cleared IND for azer-cel in progressive MS.","Secured FUJIFILM Diosynth as secondary U.S. manufacturer of BRIUMVI.","Five-year ECTRIMS data: 92% of patients free from disability progression; annualized relapse rate 0.02."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-033055","json":"https://secwatch.observer/filing/0001437749-24-033055.json","markdown":"https://secwatch.observer/filing/0001437749-24-033055.md","text":"https://secwatch.observer/filing/0001437749-24-033055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924033055/0001437749-24-033055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774924033055/tgtx20241103_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:45:17.353854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}